(Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus placebo in patients with previously treated advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback